Exact Sciences Corp
Exact Sciences Announces Second Quarter 2025 Results and Strategic Collaborations
Summary
Exact Sciences Corporation announced its financial results for the second quarter of 2025, reporting record total revenue of $811 million, an increase of 16% on a reported and core revenue basis. The company raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively. Additionally, Exact Sciences entered into a Collaboration and License Agreement with Freenome Holdings, Inc. for blood-based colorectal cancer screening tests. The company also gained Medicare coverage for its Oncodetect molecular residual disease and recurrence monitoring test. Furthermore, Exact Sciences launched its Cancerguard multi-cancer screening test and announced a multi-year productivity plan targeting $150 million in annual savings by 2026.
Profitelligence Alerts
Get alerts for EXAS
Be first to know when Exact Sciences Corp files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Exact Sciences Corp
Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.
Official SEC Documents
Advertisement